Paul Kluetz

35PUBLICATIONS
240CO-AUTHORS
Gene and molecular therapyMolecular targetsMedical biotechnology not elsewhere classifiedPharmacogenomicsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD.

Kelly J Norsworthy, Donna R Rivera, Joseph Wynne

|May 27, 2025
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.

Katherine K Barnett, Abigail R Johnson, Asha Das

Pageof 6

Frequent Collaborators

24 joint publications

Richard Pazdur

12 joint publications

Laleh Amiri-Kordestani

12 joint publications

Shenghui Tang

9 joint publications

William F Pierce